Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholders

Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholders


DUBLIN, IRELAND -- (Marketwired) -- 11/14/14 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced the pricing of a previously announced underwritten secondary offering of 11,660,445 of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of $12.05 per share. Horizon Pharma plc is not issuing new ordinary shares and will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering. The offering is expected to close on or about November 19, 2014, subject to customary closing conditions.

Morgan Stanley, Citigroup, Cowen and Company and Jefferies are acting as joint book-running managers for this offering. JMP Securities is acting as financial advisor for this offering.

A registration statement relating to the shares described above was previously filed with and became effective by rule of the Securities and Exchange Commission ("SEC"). A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and related prospectus, when available, may be obtained by contacting Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department; by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, by calling (800) 831-9146 or by emailing prospectus@citi.com; by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806; or by contacting Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. Horizon's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Beginning in January 2015, the Company expects to begin marketing PENNSAID® (diclofenac sodium topical solution) 2% w/w in the United States. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.

Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the secondary offering of ordinary shares by certain existing shareholders of Horizon Pharma plc. These forward-looking statements are based on Horizon Pharma plc's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the secondary offering. Additional risks and uncertainties relating to the secondary offering, Horizon Pharma plc and its business can be found under the caption "Risk Factors" and elsewhere in Horizon Pharma plc's Securities and Exchange Commission filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Forward-looking statements speak only as of the date of this press release, and Horizon Pharma plc undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


Media and Investors:

Robert F. Carey
Executive Vice President, Chief Business Officer
Email Contact

Elizabeth M. Higashi, CFA
Vice President, Investor Relations
Email Contact
+1 224 383-3285

Source: Horizon Pharma plc

News Provided by Acquire Media